JP2022529182A5 - - Google Patents

Info

Publication number
JP2022529182A5
JP2022529182A5 JP2021562045A JP2021562045A JP2022529182A5 JP 2022529182 A5 JP2022529182 A5 JP 2022529182A5 JP 2021562045 A JP2021562045 A JP 2021562045A JP 2021562045 A JP2021562045 A JP 2021562045A JP 2022529182 A5 JP2022529182 A5 JP 2022529182A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutically acceptable
levetiracetam
acceptable salt
therapeutic combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562045A
Other languages
English (en)
Japanese (ja)
Other versions
JP7730548B2 (ja
JP2022529182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028777 external-priority patent/WO2020214960A1/en
Publication of JP2022529182A publication Critical patent/JP2022529182A/ja
Publication of JP2022529182A5 publication Critical patent/JP2022529182A5/ja
Priority to JP2025133394A priority Critical patent/JP2025166119A/ja
Application granted granted Critical
Publication of JP7730548B2 publication Critical patent/JP7730548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562045A 2019-04-18 2020-04-17 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法 Active JP7730548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133394A JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835707P 2019-04-18 2019-04-18
US62/835,707 2019-04-18
US201962926130P 2019-10-25 2019-10-25
US62/926,130 2019-10-25
PCT/US2020/028777 WO2020214960A1 (en) 2019-04-18 2020-04-17 Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133394A Division JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Publications (3)

Publication Number Publication Date
JP2022529182A JP2022529182A (ja) 2022-06-17
JP2022529182A5 true JP2022529182A5 (enExample) 2023-04-25
JP7730548B2 JP7730548B2 (ja) 2025-08-28

Family

ID=72837945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562045A Active JP7730548B2 (ja) 2019-04-18 2020-04-17 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法
JP2025133394A Pending JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133394A Pending JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Country Status (5)

Country Link
US (1) US20220193028A1 (enExample)
EP (1) EP3955905A4 (enExample)
JP (2) JP7730548B2 (enExample)
MA (1) MA55726A (enExample)
WO (1) WO2020214960A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240423953A1 (en) * 2021-01-26 2024-12-26 The Regents Of The University Of California Methods and compositions for targeting sv2 proteins for immune regulation
CN117771240A (zh) * 2023-12-05 2024-03-29 中国人民解放军海军军医大学 一种左乙拉西坦在制备减肥药物中的应用
WO2025212556A1 (en) * 2024-04-03 2025-10-09 Prevep, Inc. Formulations comprising seletracetam and methods of use
WO2025221463A1 (en) * 2024-04-19 2025-10-23 Prevep, Inc. Pharmaceutical compositions comprising atorvastatin, or a salt thereof, and a liquid carrier

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003175091A (ja) 2001-10-03 2003-06-24 Nipro Corp 複室容器製剤
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
ATE444946T1 (de) * 2003-07-15 2009-10-15 Ono Pharmaceutical Co Verzweigte carbonsäureverbindung und deren verwendung
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20050282840A1 (en) * 2004-02-11 2005-12-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
CN102114002B (zh) 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
KR20110033304A (ko) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Ｄｎａ 손상에 대해 보호하고 신경세포 생존을 증가시키는 히스톤 디아세틸라제 1 (ｈｄａｃ1)의 활성화
AU2009279372A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
CN107095863A (zh) * 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
NZ738682A (en) * 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
AU2016315852B2 (en) * 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
EP3562553A4 (en) * 2016-12-28 2020-08-26 Expesicor LLC NON-HUMAN ANIMAL MODEL OF NEURODEGENERATIVE DISEASES
CN108379588B (zh) 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物

Similar Documents

Publication Publication Date Title
RU2484815C2 (ru) Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
Weinbroum et al. Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain
TWI405576B (zh) 疼痛疾病治療劑
TWI618539B (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
US20080089861A1 (en) Combination therapy for treatment of demyelinating conditions
JP2018501299A5 (enExample)
US20050245460A1 (en) Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
CN1720025A (zh) 加巴喷丁片剂及其制备
JP2020524702A (ja) 免疫応答を調節するｇａｂａの能力の強化
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
US10076506B2 (en) Baclofen formulations and methods for making same
US20230066347A1 (en) Ketamine treatment for amyotrophic lateral sclerosis
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
US6372792B1 (en) Method for treating anxiety, anxiety disorders and insomnia
CZ111897A3 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
WO2023155837A1 (zh) 具有镇痛和/或止痒功能的药物组合物及其用途
RU2377983C2 (ru) Препарат l-триптофана, содержащий карбидопу/бенсеразид
Yaseen et al. Analgesic Effects of Magnesium Sulphate In Patients Undergoing Laparoscopic Cholecystectomy.
JP2025505578A5 (enExample)
JP2005531594A5 (ja) 慢性痛の治療用トリプルモノアミン再取り込み阻害剤
CN103012192B (zh) 一种新型乙酰谷酰胺化合物及其药物组合物
WO2022037006A1 (zh) 一种止痛止痒药物组合物及其应用方法
CN1137686C (zh) 椎管狭窄的治疗药
Pradhan et al. Efficacy of two different doses of nebulized dexmedetomidine for attenuation of hemodynamic response to laryngoscopy and intubation: A randomized controlled trial
HK40069667A (en) Pharmaceutical composition with analgesic and/or antipruritic function and uses thereof